report ingrezza sale ahead consensu despit
season disrupt impact report revenu patient trend remain strong
fact neurocrin indic record number new patient start
opicapon track file continu think
under-valued potenti ingrezza orilissa
neurocrin report total revenu includ ingrezza
sale q/q royalti consensu total revenu
total revenu estim orilissa royalti estim
report combin ipr expens vs
inclus up-front payment voyag connect
close voyag transact march sg expens
vs neurocrin net loss vs
estim net loss end cash
ingrezza sale reflect headwind jan feb record new patient start
neurocrin report ingrezza sale q/q vs consensu
eighth consecut quarter sinc ingrezza launch
report revenu ahead consensu nonetheless believ investor
anticip approx ingrezza sale report revenu less
line buysid expect q/q vs estim
manag note ingrezza revenu impact season compris
two main compon disrupt patient access ingrezza higher gross-to-
net due medicar donut hole former broken
reset copay commerci plan need insur plan reauthor
led delay refil new scrip fill neurocrin quantifi
financi impact disrupt neurocrin previous guid
higher gross-to-net discount would creat headwind rel tonight
manag note actual disrupt slightli less altogeth
dynam disrupt ingrezza sale first six week year
nonetheless manag note sever trend suggest strong growth head
first manag note set record greatest number new
patient start ingrezza sinc launch second persist ingrezza remain
unchang -- manag initi expect third manag note
ingrezza remain prescrib drug patient td fourth overal insur
access remain good formulari provid equal access
ingrezza austedo even account austedo prefer physician
success appeal get patient ingrezza though express scrip
nation prefer formulari exclud ingrezza start juli account less
ingrezza product revenu fifth neurocrin expect modifi rebat
discount futur formulari negoti lastli neurocrin expand salesforc
fulli deploy januari dtc program began mid-month expect neurocrin
market effort continu heighten awar td among psychiatrist
patient adopt ingrezza ingrezza patient trend remain
solid made minor modif project ingrezza
estim decreas
pleas see page report import disclosur
neurocrin ingrezza valbenazin inhibitor approv
april tardiv dyskinesia follow impress ph data consult think
ingrezza becom new standard care td project achiev
 revenu orilissa gonadotropin-releas hormon gnrh antagonist
approv endometriosi snda uterin fibroid uf plan submiss
orilissa launch earli august project sale
ramp world-wide endometriosi uterin fibroid expect
outperform market launch orilissa ingrezza progress
longer term follow data
ingreaza ph trial qualiti life
orilissa file approv uf
fda meet discuss regulatori path
ingrezza achiev
revenu
orilissa achiev world-wide
sale
rest neurocrin pipelin
ingrezza gener
revenu
orilissa gener
world-wide sale
ingrezza fail achiev revenu
orilissa gener less sale
neurocrin achiev profit
must financ continu oper
focus discoveri develop novel therapeut
endocrin neurolog disord ingrezza valbenazin specif
inhibitor could effect treatment hyperkinet movement disord
tardiv dyskinesia dystonia huntington diseas ingrezza gener
strongli posit phase data tardiv dyskinesia approv april
project achiev revenu posit result orilissa ph
trial endometriosi announc earli drug approv
juli orilissa also success complet phase trial uterin fibroid
fda file anticip neurocrin receiv high-teen royalti
payment orilissa sale
last month neurocrin report posit interim result phase iia open-label
dose-escal trial corticotropin-releas factor antagonist
hydroxylas defici congenit adren hyperplasia refractori treatment
corticosteroid produc reduct least baselin
acth level patient treat
day outcom manag previous indic would indic
proof concept press releas also note meaning reduct biomark
includ adrostenedion drug well toler seriou advers event
report date
neurocrin plan meet fda discuss registr program
adult pediatr patient specif neurocrin plan
discuss registr trial endpoint optim dose move registr trial
manag note biomark absolut one endpoint assess
pivot trial wide use physician way track patient
progress howev compani also note fda may want clinic endpoint
well relat potenti steroid-spar agent endpoint might
includ metabol syndrome-rel bone miner densiti growth veloc endpoint
compani also expect initi phase iia trial pediatr patient
think could next major opportun neurocrin pipelin though
admittedli real evalu potenti requir clariti regard efficaci
safeti profil patient popul appropri therapi price
manag expect drug posit broadli avail treatment
adult pediatr patient previous suggest orphan price possibl
estim patient classic could
opportun
neurocrin orilissa elagolix partial gonadotropin-releas hormon
gnrh antagonist approv fda end juli use patient
endometriosis-associ pain neurocrin receiv upper-teen tier royalti
cap net sale began drug commerci launch august
neurocrin report royalti impli revenu
continu suggest orilissa market built gradual physician
educ patient engag latter point initi dtc campaign
coupl month ago manag view key compon launch
confer call note prior guidanc sale unchang
though orilissa sale run rate manag comfort
ramp guidanc suggest model sale gener
royalti neurocrin
anticip file nda orilissa uterin fibroid-associ bleed
trigger payment neurocrin model project orilissa
achiev revenu uterin fibroid gener royalti
opicapon nda treatment parkinson diseas episod track
submiss neurocrin prepar commerci launch
addit compani file ind complet dose sad portion
phase safeti toler pk studi novel inhibitor
develop treat sever neurolog and/or psychiatr disord outsid tourett
syndrom td mad portion trial on-going expect complet
dose neurocrin also file ind complet dose phase
sad studi intern discov first-in-class compound potenti use
treatment neurolog and/or psychiatr disord analysi data date
on-going use inform futur clinic trial neurocrin make decis
whether complet termin ingrezza t-forc platinum trial tourett
syndrom final neurocrin enter collabor voyag
develop commerci gene therapi program parkinson
diseas friedreich ataxia addit two program determin
focus discoveri develop novel
therapeut endocrin neurolog disord neurocrin
data tardiv dyskinesia td demonstr reduct involuntari
movement characterist condit major side effect
treatment-rel advers event result ingrezza approv
april ingrezza launch impress start sale
come consensu eight quarter sinc launch
consult think ingrezza good chanc becom new
standard care td project achiev revenu
orilissa elagolix partial gonadotropin-releas hormon gnrh
antagonist develop endometriosi uterin fibroid partner
neurocrin complet six phase ii two phase studi
orilissa endometriosi trial consist demonstr abil
reduc dysmenorrh non-menstru pelvic pain dyspareunia well
benign safeti profil juli orilissa receiv fda approv
endometriosis-associ pain launch drug earli august
orilissa also success complet phase program uterin fibroid
primari endpoint rank secondari endpoint hit
trial fda file anticip project orilissa achiev
world-wide sale endometriosi uterin fibroid
neurocrin receiv royalti nearli royalti rate
neurocrin complet phase healthi volunt studi
crf receptor antagonist use patient congenit adren
hyperplasia phase ii trial produc promis result pivot studi
adult set begin compound novel inhibitor
compound began phase trial expect
potenti address number neurolog and/or psychiatr condit
expect outperform market next month
launch ingrezza orilissa progress
long-term follow data ingrezza kinect re-kinect studi
file nda opicapon adjunct therapi parkinson diseas patient motor function
provid go/no-go decis continu t-forc platinum trial ingrezza tourett
complet phase trial novel vmat inhibitor healthi volunt
partner abbvi file snda elagolix uterin fibroid
fda discuss regulatori path congenit adren hyperplasia
initi phase ii proof-of-concept studi congenit adren hyperplasia children
initi phase studi congenit adren hyperplasia adult
possibl releas result t-forc platinum studi ingrezza tourett syndrom
cowen compani
cowen compani
cowen compani
 tardiv dyskinesia erat peopl erat sever tardiv dyskinesia sever would access benefit adress penetr treat ingrezza price per sale ingrezza tardiv dyskinesia sale elagolix sale elagolix uterin sale elagolix sale elagolix uterin sale elagolix rate royalti elagolix cowen
cowen compani
cowen compani
research licens income/ loss tax share outstand research licens income/ loss share outstand cowen
cowen compani
financi year growth research licens nol/tax asset tax asset nol/tax asset free year growth valu termin valu net dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
neurocrin develop drug number indic includ endometriosi uterin
fibroid tardiv dyskinesia tourett syndrom forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ evalu market potenti drug
yet approv particularli riski moreov market exclus
neurocrin franchis depend patent subject challeng gener
drugmak valu neurocrin franchis could diminish lose
protect key patent
